Diagnostic value of kinetic analysis using dynamic 18F-FDG-PET in patients with malignant primary brain tumor

Nuclear Medicine Communications

Volumn 30, Issue 8, 2009, Pages 602-609

  Kimura, Naruhide ^a   Yamamoto, Yuka ^a   Kameyama, Reiko ^a   Hatakeyama, Tetsuhiro ^b   Kawai, Nobuyuki ^b   Nishiyama, Yoshihiro ^a  

^a KAGAWA UNIVERSITY   (Japan)

^b KAGAWA UNIVERSITY   (Japan)

Author keywords

Brain tumor; Central nervous system lymphoma; Fluorine 18 fluorodeoxyglucose; Glioma; Positron emission tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GALLIUM 68; GLUCOSE;

ADULT; AGED; ARTICLE; BRAIN LYMPHOMA; BRAIN METABOLISM; BRAIN TUMOR; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL ARTICLE; COMPARTMENT MODEL; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DRUG UPTAKE; FEMALE; GLIOMA; GLUCOSE BLOOD LEVEL; GLUCOSE BRAIN LEVEL; GLUCOSE METABOLISM; GRAY MATTER; HUMAN; IMAGING SYSTEM; MALE; POSITRON EMISSION TOMOGRAPHY; QUANTITATIVE ANALYSIS; RADIOACTIVITY; RETROSPECTIVE STUDY; TUMOR DIAGNOSIS; WHITE MATTER;

ADULT; AGED; BRAIN NEOPLASMS; DIAGNOSIS, DIFFERENTIAL; FEMALE; FLUORODEOXYGLUCOSE F18; GLIOMA; GLUCOSE; HUMANS; KINETICS; LYMPHOMA; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RETROSPECTIVE STUDIES;

EID: 68349099924     PISSN: 01433636     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNM.0b013e32832e1c7d     Document Type: Article

References (23)

1. Behin A, Hoang-Xuan K, Carpentier AF, Delattre JY. Primary brain tumours in adults. Lancet 2003; 361:323-331.
2. Bühring U, Herrlinger U, Krings T, Thiex R, Weller M, Küker W. MRI features of primary central nervous system lymphomas at presentation. Neurology 2001; 57:393-396. (Pubitemid 32757581)
3. Basso U, Brandes AA. Diagnostic advances and new trends for treatment of primary central nervous system lymphoma. Eur J Cancer 2002; 38:1298-1312. (Pubitemid 34686839)
4. Abrey LE, Yahalom J, DeAngelis LM. Treatment for primary CNS lymphomas: the next step. J Clin Oncol 2000; 18:3144-3150. (Pubitemid 30677094)
5. 18F fluorodeoxyglucose and positron emission tomography. Neurology 1982; 32:1323-1329.
6. Ishikawa M, Kikuchi H, Nishizawa S, Yonekura Y. Evaluation of glucose transport in malignant glioma by PET. Acta Neurochir Suppl (Wien) 1990; 51:165-167.
7. Herholz K, Rudolf J, Heiss WD. FDG transport and phosphorylation in human gliomas measured with dynamic PET. J Neurooncol 1992; 12:159-165.
8. Delbeke D, Meyerrowitz C, Lapidus RL, Maciunas RJ, Jennings MT, Moots PL, et al. Optimal cutoff levels of F-18 fluorodeoxyglucose uptake in the differentiation of low-grade from high-grade brain tumors with PET. Radiology 1995; 195:46-52.
9. Alavi JB, Alavi A, Chawluk J, Kushner M, Powe J, Hickey W, et al. PET in patients with glioma. A predictor of prognosis. Cancer 1988; 62:1074-1078.
10. Kaschten B, Stevenaert A, Sadzot B, Deprez M, Degueldre C, Fiore GD, et al. Preoperative evaluation of 54 gliomas by PET with fluorine-18- fluorodeoxyglucose and/or carbon-11-methionine. J Nucl Med 1998; 39:778-785. (Pubitemid 28216722)
11. Sasaki M, Kuwabara Y, Yoshida T, Nakagawa M, Fukumura T, Mihara F, et al. A comparative study of thallium-201 SPET, carbon-11 methionine PET and fluorine-18 fluorodeoxyglucose PET for the differentiation of astrocytic tumours. Eur J Nucl Med 1998; 25:1261-1269. (Pubitemid 28446052)
12. Wong TZ, Westhuizen GJ, Coleman RE. Positron emission tomography imaging of brain tumor. Neuroimag Clin N Am 2002; 12:615-626. (Pubitemid 36015495)
13. Spence AM, Muzi M, Mankoff DA, O'Sullivan SF, Link JM, Lewellen TK, et al. 18F-FDG PET of gliomas at delayed intervals: improved distinction between tumor and normal gray matter. J Nucl Med 2004; 45:1653-1659. (Pubitemid 47618471)
14. Rosenfeld SS, Hoffman JM, Coleman RE, Glantz MJ, Hanson MW, Schold SC. Studies of primary central nervous system lymphoma with fluorine-18- fluorodeoxyglucose positron emission tomography. J Nucl Med 1992; 33:532-536.
15. Hoffman JM,Waskin HA, Schifter T, Hanson MW, Gray L, Rosenfeld S, et al. FDG-PET in differentiating lymphoma from nonmalignant central nervous system lesions in patients with AIDS. J Nucl Med 1993; 34:567-575. (Pubitemid 23115656)
16. Roelcke U, Leender KL. Positron emission tomography in patients with primary CNS lymphomas. J Neurooncol 1999; 43:231-236. (Pubitemid 29488380)
17. Palmedo H, Urbach H, Bender H, Schlegel U, Schmidt-Wolf IGH, Matthies A, et al. FDG-PET in immunocompetent patients with primary central nervous system lymphoma: correlation with MRI and clinical follow-up. Eur J Nucl Med Mol Imaging 2006; 33:164-168. (Pubitemid 43152883)
18. Nishiyama Y, Yamamoto Y, Monden T, Sasakawa Y, Kawai N, Satoh K, et al. Diagnostic value of kinetic analysis using dynamic FDG PET in immunocompetent patients with primary CNS lymphoma. Eur J Nucl Med Mol Imaging 2007; 34:78-86. (Pubitemid 44885557)
19. Phelps ME, Huang SC, Hoffman EJ, Selin C, Sokoloff L, Kuhl DE. Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18) 2-fluoro-2-deoxy-D-glucose: validation of method. Ann Neurol 1979; 6:371-388.
20. 18F] fluoro-D-glucose positron emission tomography imaging: a method with validation based on multiple methodologies. Mol Imaging Biol 2003; 5:32-41.
21. 18F]-2-fluoro-2-deoxy-D-glucose. J Cereb Blood Flow Metab 1984; 4:212-223.
22. Huang SC, Phelps ME, Hoffman EJ, Sideris K, Selin CJ, Kuhl DE. Noninvasive determination of local cerebral metabolic rate of glucose in man. Am J Physiol 1980; 238:E69-E82.
23. Gjedde A,Wienhard K, Heiss WD, Kloster G, Diemer NH, Herholz K, et al. Comparative regional analysis of 2-fluoro deoxyglucose and methyl glucose uptake in brain of four stroke patients with special reference to the regional estimation of the lumped constant. J Cereb Blood Flow Metab 1985; 5:163-178.